Company:  SIGA TECHNOLOGIES INC (SIGA)
Form Type:  10-K
Filing Date:  3/10/2014 
CIK:  0001010086 
Address:  660 MADISON AVENUE
SUITE 1700
 
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.30  
Change: 
0.07 (3.14%)  
Trade Time: 
03:53 PM EST  
Market Cap: 
$124.85M
Trade SIGA now with 

© 2016  
Description of Business
We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX(TM), also known as Tecovirimat or ST-246®, an orally administered antiviral drug that targets orthopoxvirus infections. While TPOXX(TM) is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that is being developed with support from BARDA and delivered to the Strategic Stockpile under Project BioShield. BARDA Contract - TPOXX(TM), also known as Tecovirimat or ST-246® On May 13, 2011, the Company signed the BARDA Contract pursuant to which we agreed to deliver two million courses of TPOXX(TM) to the Strategic Stockpile. The BARDA Contract is worth approximately $470 million, including $409.8 million for manufacture and delivery of 1.7 million courses of TPOXX(TM) and $60 million of potential reimbursements related to development and supportive activities (the "Base Contract").
Register and access this filing in:     
  FORM 10-K
    Item 1A. Risk Factors
    Item 1B. Unresolved Staff Comments
    PART I
      Item 2. Properties
      Item 3. Legal Proceedings
      Item 4. Mine Safety Disclosures
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6. Selected Financial Data
      Item 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
        Liquidity and Capital Resources
      Item 7A. Quantitative and Qualitative Disclosures About ...
        BALANCE SHEET
        Report of Independent Registered Public Accounting Firm
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures
      Item 9B. Other Information
    PART III
      Item 10. Directors, Executive Officers, and Corporate Governance
      Item 11. Executive Compensation
      Item 12. Security Ownership of Certain Beneficial Owners and ...
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accountant Fees and Services
    PART IV
      Item 15. Exhibits and Financial Statement Schedules
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    Certification by Chief Executive Officer Pursuant to
  EXHIBIT 31.2
    Certification by Chief Executive Officer Pursuant to
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO